Biotech Firm With Great Potential

LAS VEGAS, NV / ACCESSWIRE / September 12, 2016 / Early last month GlaxoSmithKline ($GSK) announced a major new joint venture with Verily — once Google Life Sciences — with the hope of creating the first generation of bioelectronic medicines for chronic diseases.

The company committed to investing $715 million over the next 7 years into a Joint Venture with Verily focused on building devices targeting arthritis, diabetes and asthma.

Verily, a part of Alphabet ($GOOG), emerged from its secretive Google X division and has recently become its own unit focused on big data and devices, such as a “smart” contact lens and surgical robots. This venture will be called Galvani Bioelectronics (named after the Italian 18th century pioneer in the field of bioelectricity Luigi Aloisio Galvani), will be 55% owned by GSK and 45% by Verily.

The main goal of this venture will be to produce an implantable bioelectronic device.

Bioelectronic medicine essentially works like this: many of the processes of the human body are controlled by electrical signals firing between the nervous system and the body’s organs, which may become distorted in many chronic diseases. Bioelectronic medicine’s vision is to employ the latest advances in biology and technology to interpret this electrical conversation and to correct the irregular patterns found in disease states, using miniaturized devices attached to individual nerves. If successful, this approach offers the potential for a new therapeutic modality alongside traditional medicines and vaccines.

If you’re looking to invest in bioelectronic medicine, however, this joint venture may not be the best route as a company already has a product targeting inflammation like this joint venture seeks to achieve and it’s also NON INVASIVE!

That company is Endonovo Therapeutics, Inc. (ENDV).

ENDV is developing bioelectronic medicines targeting unmet needs in inflammatory conditions in vital organs. One of Endonovo’s lead programs is its Immunotronics platform, a non-invasive, non-implantable device for treating and/or preventing vital organ failure, which can result from an out of control inflammatory response to injury and infection. The initial focus of the company is to use the Immunotronics platform to treat acute and chronic inflammatory conditions of the liver, such as liver injury and possibly Non-Alcoholic Steatohepatitis (NASH).

Here are a few highlights we believe make ENDV a better option in bioelectronics than GSK:

Endonovo Immunotronics and Cytotronics platforms are built upon technology discovered at the National Aeronautics and Space Administration (NASA).
ENDV’s technology has been shown to be a potent non-invasive anti-inflammatory device in a pharmaceutical “gold standard” model of acute inflammation.
Non-invasive technology targets cells and organs directly rather than relying on vagus nerve stimulation used by implantable devices.
Possible Humanitarian Device Exemption (HDE) pathway for treating acute liver failure is a potential gateway indication for Endonovo’s platform.

There is also the possibility that this new GSK joint venture may find that ENDV’s product is better than what they come up with, and actually decide to acquire the company which could be a major boon for ENDV investors.

This week is a great time to consider taking a long look at ENDV.

Here’s a few other biotechs in the news:

Geron Corporation (GERN) company has made a really nice uptick over the course of the last week. Keep an eye on this one for another possible breakout!

Esperion Therapeutics, Inc. (ESPR) this stock is down considerably from just a few months back, put this one on your watchlist for a possible swing trade.

Galena Biopharma, Inc. (GALE) had a number of Reuters analysts recently comment on the stock. Currently the company has earned ‘Buy’ from 1 equity analyst. 0 analysts hold a ‘Sell’ rating for the stock. 2 analysts have suggested the company is a ‘Hold’. ‘Underperform’ verdict was shared by 0 analyst and ‘Outperform’ recommendation was issued by 1 analyst. The company has an Average Rating of 2.25 based on analysts tracked by Thomson Reuters.

Immunomedics, Inc. (IMMU) announced that the Company will present at three upcoming investor conferences:

Credit Suisse 2016 Antibody Day at 8:00 a.m. Eastern Time on Wednesday, September 7, 2016 at Credit Suisse’s campus in New York City;
2016 Wells Fargo Healthcare Conference at 3:30 pm Eastern Time on Thursday, September 8, 2016 at the Westin Waterfront in Boston, MA; and
Rodman & Renshaw 18th Annual Global Investment Conference at 4:15 pm on Tuesday, September 13, 2016 at the Lotte New York Palace Hotel in New York City.

The Company will also participate in one-on-one meetings with institutional investors at these conferences.

Legal Disclaimer

Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. ACR Communication, LLC. which owns Microcapspeculators.com, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. ACR Communication, LLC. which owns, Microcapspeculators.com may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. ACR Communication LLC. which owns Microcapspeculators.com may be compensated for its services in the form of cash-based compensation or in equity in the companies it writes about, or a combination of the two. For Full Legal Disclaimer Click Here.

SOURCE: ACR Communication, LLC

ReleaseID: 445128